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Abstract This study aimed to systematically review the prog-
nostic value of pretransplant 18F-fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) in refractory/
relapsed Hodgkin lymphoma treated with autologous stem
cell transplantation (SCT). MEDLINE was systematically
searched for appropriate studies. Included studies were meth-
odologically appraised. Results of individual studies were me-
ta-analyzed, if possible. Eleven studies, comprising a total of
745 refractory/relapsed Hodgkin lymphoma patients who
underwent FDG-PET before autologous SCT, were included.
The overall methodological quality of these studies was mod-
erate. The proportion of pretransplant FDG-PET positive pa-
tients ranged between 25 and 65.2 %. Progression-free surviv-
al ranged between 0 and 52 % in pretransplant FDG-PET
positive patients, and between 55 and 85 % in pretransplant
FDG-PET negative patients. Overall survival ranged between
17 and 77 % in pretransplant FDG-PET positive patients, and
between 78 and 100 % in FDG-PET negative patients. Based
on five studies that provided sufficient data for meta-analysis,
pooled sensitivity and specificity of pretransplant FDG-PET
in predicting treatment failure (i.e., either progressive, residu-
al, or relapsed disease) were 67.2 % (95 % confidence interval
[CI] 58.2–75.3 %) and 70.7 % (95 % CI 64.2–76.5 %), respec-
tively. Based on two studies that provided sufficient data for
meta-analysis, pooled sensitivity and specificity of pretransplant
FDG-PET in predicting death during follow-up were 74.4 %
(95 % CI 58.8–86.5 %) and 58.0 % (95 % CI 49.3–66.3 %),
respectively. In conclusion, the moderate quality evidence sug-
gests pretransplant FDG-PET to have value in predicting out-
come in refractory/relapsed Hodgkin lymphoma patients treated
with autologous SCT. Nevertheless, a considerable proportion
of pretransplant FDG-PET positive patients remains disease free
and a considerable proportion of pretransplant FDG-PET nega-
tive patients develops disease relapse after autologous SCT.
Keywords Autologous stemcell transplantation . FDG-PET .
Hodgkin lymphoma .Meta-analysis . Systematic review
Introduction
More than 90 % of patients with limited-stage and up to 80 %
of patients with advanced-stage Hodgkin lymphoma achieve
long-term disease-free survival with standard first-line thera-
pies [1]. Unfortunately, a non-negligible fraction of Hodgkin
lymphoma patients develops refractory/relapsed disease.
Randomized trials have demonstrated the potential benefit of
salvage chemotherapy followed by consolidation with high-
dose therapy (HDT) and autologous stem cell transplantation
(SCT) as second-line therapy [2, 3]. With this treatment regi-
men, more than 50 % of patients can be cured [2–6]. Patients
who relapse after HDT and autologous SCT have dismal out-
comes [7, 8]. Timely identification of non-responders to stan-
dard second-line therapy is crucial to offer them the opportu-
nity to switch to more intensive and potentially more effective
therapies such as extended salvage therapy, additional radia-
tion therapy, allogeneic SCT, tandem SCT, or the addition of
recently developed novel drugs such as brentuximab vedotin.
Several parameters have proven to be predictive of poor out-
come in patients with relapsed Hodgkin lymphoma, including
presalvage anemia, hypoalbuminemia, lymphopenia, pres-
ence of B symptoms, extranodal involvement at relapse,
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Karnofsky score <90 %, and a time interval between first-line
therapy and relapse detection of less than 1 year [4, 9–12].
Another method that might provide prognostic information is
18F-fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET). FDG-PET is widely used for staging Hodgkin
lymphoma [13, 14], but may also be performed during treat-
ment to identify non-responders. In newly diagnosed Hodgkin
lymphoma, FDG-PETafter 1–4 cycles of first-line therapy has
shown to have prognostic value, although results are hetero-
geneous among different studies [15]. Over the past few years,
several studies have also evaluated the prognostic value of
pretransplant FDG-PET in refractory/relapsed Hodgkin lym-
phoma patients undergoing autologous SCT. However, there
may be variability among individual studies with regard to
internal validity (i.e., risk of bias) and external validity (i.e.,
generalizability of study results). A systematic review and
meta-analysis are required to better comprehend the value of
FDG-PET in this setting. The purpose of this study was there-
fore to systematically review and meta-analyze published data
on the prognostic value of pretransplant FDG-PET in patients
with refractory/relapsed Hodgkin lymphoma treated with sal-
vage therapy, HDT, and autologous SCT.
Materials and methods
Search strategy
Medline was searched using the PubMed interface for original
studies on the prognostic value of pretransplant FDG-PET in
refractory/relapsed Hodgkin lymphoma, from start date to 12
July 2015. The search strategy is displayed in Table 1.
References of the included studies were scrutinized for suit-
able references that were not retrieved by the initial PubMed
search.
Study selection
Original studies reporting on the value of pretransplant FDG-
PET in predicting patient outcome (either number of progres-
sive, residual, or relapsed diseases, number of deaths,
progression-free survival, or overall survival) in refractory/
relapsed Hodgkin lymphoma treated with salvage therapy,
HDT, and autologous SCT were eligible for inclusion.
Studies were excluded if not written in English, Spanish,
French, German, Italian, or Dutch. Articles without original
patient data, such as reviews, editorials, letters, and confer-
ences abstracts, were excluded. Articles with less than 10 pa-
tients and articles from which the same patient data were used
in a more recent article were also excluded. Articles in which
patients with Hodgkin lymphoma could not be separated from
patients with other lymphoma subtypes, articles in which pa-
tients receiving allogeneic SCT could not be separated from
patients receiving autologous SCT, and articles in which pa-
tients undergoing FDG-PET could not be separated from pa-
tients who were examined with other imaging techniques
(e.g., gallium scans) were excluded. Articles in which therapy
was modified on the basis of the pretransplant FDG-PET re-
sult (except for patients who were allocated to another salvage
regimen in case of evident non-response or disease progres-
sion during salvage treatment, which is considered reflective
of clinical practice) were not included into the main analysis,
but addressed separately. Titles and abstracts of all studies that
were obtained by the PubMed search were screened using
these inclusion and exclusion criteria. Articles that were cer-
tainly ineligible were excluded at this stage. The remaining
articles were then retrieved in full-text format to make a final
decision as to whether they met the criteria to be included in
this systematic review and meta-analysis.
Methodological quality assessment
The Quality in Prognosis Studies (QUIPS) criteria were used
to assess the methodological quality of included studies [16].
The QUIPS criteria include six different domains: risk of bias
in study participation (Bdo the study data available [i.e., pa-
tients not lost to follow-up] adequately represent the study
sample?^), prognostic factor measurement (Bis the prognostic
factor measured in a similar way for all participants?^), out-
come measurement (Bis the outcome of interest measured in a
similar way for all participants?^), study confounding (Bhave
important potential confounding factors appropriately been
accounted for?^), and statistical analysis and reporting (Bis
the statistical analysis appropriate, and are all primary out-
comes reported^) [16]. Risk of bias was scored as low, mod-
erate, or high for each of these six domains [16].
Meta-analysis
Studies were eligible for meta-analysis if they provided suffi-
cient data to construct 2×2 contingency tables to calculate the
sensitivity and specificity of pretransplant FDG-PET in
predicting treatment failure (i.e., either progressive, residual,
or relapsed disease) and/or death during follow-up. This meta-
analysis did not include studies that applied pretransplant
Table 1 Medline search performed using the PubMed interface on 12
July 2015
No. Search string No. of hits
in Medline
1. Fluorodeoxyglucose or 2-fluoro-2-deoxy-D-glucose
or FDG or 18F-FDG or positron emission
tomography or PET
89,372
2. Hodgkin or Hodgkin’s or Hodgkins 81,948
3. No. 1 and no. 2 1768
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FDG-PET-adapted therapies. To explore whether using differ-
ent thresholds in studies included may have affected sensitiv-
ity or specificity, Spearman ρ (comparison of the logit of the
sensitivity and logit of 1-specificity) was calculated.
Spearman ρ>0.6 was considered to demonstrate the presence
of a threshold effect [17]. If a threshold effect was absent,
summary estimates of sensitivity and specificity were calcu-
lated, using the DerSimonian and Laird method [18]. The
Higgins and Thompson test was used to assess heterogeneity
in diagnostic odds ratios (DORs) across individual studies
[19]. Heterogeneity was defined as I2 exceeding 50 %. The
DOR is an overall measure of accuracy of a diagnostic test that




The Medline search revealed 1768 articles (Table 1). After
screening titles and abstracts, 30 remained. Of these, 5 were
excluded because these studies did not allow separate data
extraction of patients with Hodgkin lymphoma from those
with other non-Hodgkin lymphoma subtypes, 3 were exclud-
ed because these studies included less than 10 patients with
Hodgkin lymphoma, 3 were excluded because these studies
reported insufficient data about the prognostic consequences
of the pretransplant FDG-PETstatus, 2 were excluded because
these studies mixed pretransplant FDG-PET and gallium scan
findings, 1 was excluded because patients undergoing autolo-
gous SCT could not be separated from patients undergoing
allogeneic SCT, 1 was excluded because only patients with
complete remission at pretransplant FDG-PETwere included,
and 1 was excluded because it included a group of patients
that was treated without SCT and who could not be separated
from patients undergoing autologous SCT. Finally, 14 articles,
of which 11 did not change the therapy on the basis of the
pretransplant FDG-PET results, and 3 applied pretransplant
FDG-PET-adapted therapy, were included. The characteristics
of these studies are displayed in Tables 2 and 3.
Methodological quality
The methodological quality assessment using the QUIPS
criteria is displayed in Table 4. Overall, the methodological
quality was moderate. There was moderate risk of bias for the
domain of study inclusion in six studies, because five studies
[22, 23, 25, 26, 29] did not report whether refractory/relapsed
disease was histologically confirmed before initiation of sal-
vage therapy and one study [24] reported that refractory/
relapsed disease was not histologically verified in 50/141 pa-
tients. There was moderate risk of bias for the domain of
prognostic factor measurement in six studies, because four
studies did not report the whether a stand-alone PET system
or integrated PET/CT system was used [21–23, 34], and two
studies [24, 29] included patients who underwent stand-alone
FDG-PET. In addition, there was high risk of bias for the
domain of prognostic factor measurement in three studies
[27, 30, 31], because these studies used stand-alone FDG-
PET systems and did not use standardized international
FDG-PET interpretation criteria. There was moderate risk of
bias in all 14 included studies, because none of these studies
reported that refractory/relapsed disease after autologous SCT
was histologically verified. Finally, there was moderate risk of
bias for study confounding in 12 of 14 studies [21–28, 30,
32–34], because these studies included patients treated with
heterogeneous treatment regimens.
Prognostic value pretransplant FDG-PET
Results of the 11 studies on the prognostic value of
pretransplant FDG-PET are shown in Table 5. The proportion
of pretransplant FDG-PET positive patients ranged between
25 and 65.2 %. Progression-free survival ranged between 0
and 52 % in pretransplant FDG-PET positive patients, and
between 55 and 85 % in pretransplant FDG-PET negative
patients. Overall survival ranged between 17 and 77 % in
pretransplant FDG-PET positive patients, and between 78
and 100 % in FDG-PET negative patients.
Based on five studies that provided sufficient data for meta-
analysis, pooled sensitivity and specificity of pretransplant
FDG-PET in predicting treatment failure (i.e., either progres-
sive, residual, or relapsed disease) were 67.2 % (95 % confi-
dence interval [CI] 58.2–75.3 %) and 70.7 % (95 % CI 64.2–
76.5 %), respectively. Note that there was no threshold effect
(Spearman ρ=0.6, P=0.285) and no heterogeneity in DORs
among these five studies (I2 =0.0 %).)
Based on two studies that provided sufficient data for meta-
analysis, pooled sensitivity and specificity of pretransplant
FDG-PET in predicting death were 74.4 % (95 % CI 58.8–
86.5 %) and 58.0 % (95 % CI 49.3–66.3 %), respectively.
Note that the presence of a threshold effect and heterogeneity
in DORs could not statistically be assessed with only two
studies.
Pretransplant FDG-PET-adapted therapeutic studies
Three studies were included that applied FDG-PET-adapted
therapy. Two studies [32, 34] directed the therapy in a system-
atic fashion (applied extended lines of salvage therapy in
FDG-PET positive patients) and showed that patients who
acquired FDG-PET negative status after extended lines of
salvage therapy (91 and ±80 %, respectively) had a similar
PFS as those who acquired FDG-PET negative status after
standard therapy (92 % and ±80, [32, 34]. On the other hand,
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patients who did not acquire FDG-PET negative status had a
worse prognosis (46 and ± 30 %, [32, 34]. One retrospective
study [33] applied tandem autologous SCT in high-risk pa-
tients (where risk was determined on the basis of the
pretransplant FDG-PET result and other factors [33]).
Patients with pretransplant FDG-PET positive status treat-
ed with tandem autologous SCT had a better 5-year PFS
(43 %) than those treated with single autologous SCT
(0 %), whereas this benefit in terms of 5-year PFS was
less clear in those with a negative pretransplant FDG-PET
(87 vs. 75 %, respectively [33]).
Discussion
The present systematic review and meta-analysis show that
the patients with a pretransplant FDG-PETscan that is positive
for residual disease generally have a worse outcome (both in
terms of progression-free survival and overall survival) than
those with a negative pretransplant FDG-PET scan. The pre-
dictive value of pretransplant FDG-PET appears to be moder-
ate, however, with pooled sensitivity and specificity pairs of
67.2 and 70.7 % for the prediction of treatment failure, and
74.4 and 58.0 % for predicting death during follow-up. Since
both false-positives and false-negatives are not uncommon, it
is questionable whether incorporating pretransplant FDG-PET
results in treatment planning in routine clinical practice is
justified at this moment.
Several prediction rules have been developed to predict
outcome in patients with relapsed/refractory Hodgkin lym-
phoma undergoing autologous SCT: the Memorial Sloan-
Kettering Cancer Center (MSKCC) prognostic model [10],
the Grupo Espanol de Linfomas/Trasplante Autologo de
Medula Osea (GEL/TAMO) score [4], the Simplified
Validated Prognostic Model of the Center for International
Blood and Marrow Transplant Research (CIBMTR) [12],
and the Adapted Prognostic Score which was developed using
the cohort of the HDR2 trial [37]. The MSKCC found the
three factors duration of remission <1 year, presence of
extranodal disease before salvage therapy, and presence of B
symptoms before salvage therapy, to be significantly predic-
tive of outcome after autologous SCT [10]. With a median
follow-up of 43 months, progression-free survival was 83 %
for patients with zero or one risk factor, 27 % for patients with
two risk factors, and 10 % for patients with all three risk
factors [10]. The GEL/TAMO group identified the following
prognostic factors: presence of extranodal disease, chemother-
apy refractory disease, and duration of complete remission
<12 months prior to relapse [4]. Patients with 0–1, 2, and 3
risk factors had long-term progression-free survival rates of
71, 51, and 18 %, respectively [4]. The CIBMTR prognostic
model [12] found three significant independent predictive
Table 3 FDG-PET imaging and interpretation methods, and criteria for treatment failure that were used in the included studies








Gentzler et al. [21] (2014) NR Nuclear medicine radiologist Yes (all cases) NR
Nieto et al. [22] (2013) NR NR NR NR
Cocorocchio et al. [23] (2013) NR NR NR NR
Akhtar et al. [24] (2013) Stand-alone or hybrid
FDG-PET/CT
Two nuclear medicine physicians Yes: 91
No: 50
NR
Sucak et al. [25] (2011) Hybrid FDG-PET/CT Two nuclear medicine physicians NR NR
Smeltzer et al. [26] (2011) Hybrid FDG-PET/CT Two nuclear medicine physicians NR NR
Mocikova et al. [27] (2011) Stand-alone FDG-PET or
hybrid FDG-PET/CT
Local nuclear medicine report Yes (all cases) NR
Arai et al. [28] (2010) Hybrid FDG-PET/CT NR Yes (all cases) NR
Castagna et al. [29] (2009) Stand-alone FDG-PET Experienced nuclear medicine
physician
NR NR
Jabbour et al. [30] (2007) Stand-alone FDG-PET or
hybrid FDG-PET/CT
NR Yes (all cases) NR
Schot et al. [31] (2007) Stand-alone FDG-PET Two independent reviewers Yes (all cases) NR
Pretransplant FDG-PET-adapted therapeutic trials
Moskowitz et al. [32] (2015) Hybrid PET/CT Nuclear medicine physician Yes (all cases) NR
Devillier et al. (2012) [33] Hybrid PET/CT Nuclear medicine physician Yes NR
Moskowitz et al. (2012) [34] NR Nuclear medicine physician Yes (all cases) NR
NR not reported
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factors in the multivariate analysis and developed the follow-
ing risk score: Karnofsky performance score <90 and chemo-
therapy resistance at autologous SCTwere assigned one point,
and three or more chemotherapy regimens before autologous
SCT and extranodal disease present at autologous SCT were
assigned two points. Based on the sum score for the four risk
factors, three groups were identified: low (0 points), interme-
diate (1–3 points), or high (4–6 points). The 4 years
progression-free survival for the low, intermediate, and high
risk groups were 71, 60, and 42 %, respectively [12]. Finally,
the Adapted Prognostic Score of the HDR2 trial [37] identi-
fied the risk factors presence of stage IV at relapse, anemia,
and early or multiple relapse. Patients with 0, 1, 2, and 3 of
these risk factors had a 3-year progression-free survival of
approximately 80, 70, 50, and 15%, respectively. Future stud-
ies are required to compare pretransplant FDG-PET to these
clinical risk assessment models and to assess whether the for-
mer has any additional value to the latter.
Three prospective studies in which the treatment strategy
was based on the pretransplant FDG-PET result have been
published. A study by Moskowitz et al. [34] published in
2012 included patients with histologically proven refractory/
relapsed Hodgkin lymphoma who were treated with salvage
ifosfamide, carboplatin, etoposide (ICE) chemotherapy. After
salvage chemotherapy, patients underwent a restaging FDG-
PET. Positive scans were defined by site of disease as follows:
supradiaphragmatic Hodgkin lymphoma, FDG uptake greater
than mediastinal blood pool; and infradiaphragmatic Hodgkin
lymphoma, FDG uptake greater than abdominal aortic blood
pool. If the FDG-PET scan was negative, patients proceeded
to radiotherapy, HDT, and autologous SCT, whereas patients
with positive FDG-PET scans were additionally treated with
2 cycles of gemcitabine, vinorelbine and liposomal doxorubi-
cin (GVD), followed by a second restaging FDG-PET scan,
radiotherapy, HDT, and autologous SCT. Fifty-eight (60 %) of
patients received an FDG-PET based complete response after
ICE chemotherapy. Of the remaining 36 patients, 33 were
treated with additional GVD, of whom 17 acquired a post
GVD negative FDG-PET status. The event-free survivals
(EFSs) of patients who achieved a negative FDG-PET after
ICE or GVD were almost similar (estimated 4-year EFS ap-
proximately 80%), whereas those who did not acquire a FDG-
PET negative status had a worse prognosis (estimated 4-year
EFS 28.6 %). Moskowitz et al. [34] concluded that their study
provides evidence that the goal of salvage therapy in patients
with Hodgkin lymphoma should be a negative FDG-PETscan
before HDT and autologous SCT. Unfortunately, their study
did not report the effect of their treatment strategy and/or
FDG-PET status on the overall survival. Consequently, it still
remains unclear whether this treatment strategy will result in a
long-term benefit in overall survival. Patients with post HDT
and autologous SCT residual disease may have been cured
with third-line therapies, thereby relatively decreasing the sur-
vival benefit of Moskowitz et al.’s [34] treatment strategy. On
top of that, a third-line therapy only exposed the patients in
whom second-line therapy failed to additional therapies, and
not the entire group of post-salvage FDG-PET positive pa-
tients. Of note, 5 of 38 post ICE positive patients became
transplant ineligible after the GVD courses, and this number
might have been lower when HDT and autologous SCTwere
applied directly after the ICE/augmented ICE courses. Finally,
Moskowitz et al. [34] did not report whether residual disease














Gentzler et al. [21] (2014) Low Low Moderate Moderate Moderate Low
Nieto et al. [22] (2013) Moderate Low Moderate Moderate Moderate Low
Cocorocchio et al. [23] (2013) Moderate Low Moderate Moderate Moderate Low
Akhtar et al. [24] (2013) Moderate Low Moderate Moderate) Moderate Low
Sucak et al. [25] (2011) Moderate Low Low Moderate Moderate Low
Smeltzer et al. [26] (2011) Moderate Low Low Moderate Moderate Low
Mocikova et al. [27] (2011) Low Low High Moderate Moderate Low
Arai et al. [28] (2010) Low Low Low Moderate Moderate Low
Castagna et al. [29] (2009) Moderate Low Moderate Moderate Low Low
Jabbour et al. [30] (2007) Low Low High Moderate Moderate Low
Schot et al. [31] (2007) Low Low High Moderate Low Low
Pretransplant FDG-PET-adapted therapeutic trials
Moskowitz et al. [32] (2015) Low Low Low Moderate Moderate Low
Devillier et al. (2012) [33] Low Low Low Moderate Moderate Low
Moskowitz et al. (2012) [34] Low Low Moderate Moderate Moderate Low
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after autologous SCT was histologically verified. Another
study by Moskowitz et al. [32] published in 2015 included
45 patients who were treated with 2 cycles of brentuximab
vedotin as first-line salvage treatment, followed by an FDG-
PET scan, which was positive in 33 and negative in 12 pa-
tients. Positive patients were treated with second-line salvage
therapy by ICEwhereas negative patients were directly treated
with HDT and autologous SCT. Thirty-two of 33 patients had
FDG-PET scans after salvage ICE, of whom 22 were negative
and 10 remained positive, followed by HDT and autologous
SCT in all 32 cases. The median follow-up was 20 months. At
2 years, EFS of patients who were FDG-PET negative after
brentuximab vedotin therapy was 92 %, and that of those who
were FDG-PET negative after brentuximab vedotin and addi-
tional ICE was 91 %. Patients who were still FDG-PET pos-
itive after brentuximab and vedodotin and ICE had an EFS of
46 %. Unfortunately, this study did not report the influence of
the FDG-PET status on the overall survival either. Finally,
Devillier et al. [33] performed a retrospective analysis of 111
patients with relapsed/refractory Hodgkin lymphoma.
Pretransplant FDG-PETstatus was considered in order to select
subsequent therapy by means of either HDT with autologous
SCT or tandem HDTwith autologous SCT. The choice of sin-
gle or tandem transplantation was made on the basis of both
risk factors (interval from end of first-line therapy to relapse
<12months; Ann-Arbor stage III or IVat relapse; and relapse in
a previously irradiated field) at relapse and PET response after
salvage therapy. After salvage therapy, 85 patients acquired
pretransplant FDG-PET negative status, of whom 50
underwent tandem autologous SCT, and 26 acquired
pretransplant FDG-PET positive status, of whom 12 underwent
tandem autologous SCT. Five-year progression-free survival
and overall survival were 75 and 84 % in pretransplant FDG-
PET negative, and 0 and 47% in pretransplant positive patients
treated with a single HDT and autologous SCT, respectively.
On the other hand, 5-year progression-free survival and overall
survival were 87 and 93 % in pretransplant negative, and 43
and 56 % in pretransplant FDG-PET positive patients treated
with tandem HDT and autologous SCT. In other words, partic-
ularly pretransplant FDG-PET positive patients appeared to
benefit from tandem HDT and autologous SCT. However, it
should be realized that this study included a low number of
pretransplant FDG-PET positive patients and that other risk
factors were considered in the determination of the treatment
strategy. Thus, although the first results of FDG-PET adapted
trials are encouraging, the survival benefit of this treatment
strategy has not convincingly been proven.
The present systematic review and meta-analysis had sev-
eral limitations. First, methodological quality of studies in-
cluded was moderate. Particularly the inter- and intrastudy
variability in salvage regimens and number of therapy cycles
might have influenced the predictive value of pretransplant
FDG-PET. During first-line therapy, the predictive value of
interim FDG-PET has already been shown to be influenced
by pretreatment risk factors and the treatment regimen that is
used [15]. It is not unlikely that these results can be extrapo-
lated to the second-line therapy setting. Second, although
studies changing treatment strategy on the basis of the
pretransplant FDG-PET result were separated from those
who did not apply pretransplant FDG-PET-adapted therapy,
it cannot be excluded that some of the included studies might
have applied FDG-PET based therapies without clearly de-
scribing this in their methodology. Particularly in retrospective
studies, the FDG-PET result might have driven clinicians to
alter treatment planning (e.g., additional cycles of salvage
therapy) and order additional FDG-PET scans before the ac-
tual autologous SCT. Third, only five studies reported suffi-
cient data for a meta-analysis on the value of pretransplant
FDG-PET in predicting treatment failure, and only two studies
reported sufficient data for a meta-analysis on the value of
pretransplant FDG-PET in predicting overall survival.
Fourth, data on interobserver agreement in FDG-PET inter-
pretation were not reported by individual studies.
Interobserver variability of FDG-PET interpretation during
therapy (kappa values of 0.66–0.84 have been reported in such
settings [38, 39]) may have affected the results of both indi-
vidual studies and this meta-analysis.
In conclusion, the moderate quality evidence suggests
pretransplant FDG-PET to have value in predicting outcome
in refractory/relapsed Hodgkin lymphoma patients treated with
autologous SCT. Nevertheless, a considerable proportion of
pretransplant FDG-PET positive patients remains disease free
and a considerable proportion of pretransplant FDG-PET neg-
ative patients develops disease relapse after autologous SCT.
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